Portal de Periódicos da CAPES

Efficacy of taxane regimens in patients with metastatic angiosarcoma

2011; John Libbey Eurotext; Volume: 21; Issue: 4 Linguagem: Inglês

10.1684/ejd.2011.1403

1952-4013

Taizo Hirata, Kan Yonemori, Masashi Ando, Akihiro Hirakawa, Hitoshi Tsuda, Tadashi Hasegawa, Hirokazu Chuman, Kenjiro Namikawa, Naoya Yamazaki, Yasuhiro Fujiwara,

Sarcoma Diagnosis and Treatment

The purpose of this study was to evaluate the efficacy of taxane regimens in patients with metastatic angiosarcoma. Forty-one patients with metastatic angiosarcoma treated at the National Cancer Center Hospital between January 1982 and January 2009 were retrospectively classified into 3 groups according to the treatment type: (i) taxane (n=11), (ii) non-taxane (n=14), and (iii) best supportive care (BSC; n=16) groups. The taxane group received paclitaxel (n=6), docetaxel (n=4), or albumin-bound paclitaxel (n=1), and the non-taxane group received mainly doxorubicin-containing regimens (n=12). The differences in progression-free survival (PFS) among the 3 groups were statistically significant (P<0.001). After adjusting for prognostic factors, the taxane group had significantly longer PFS than the non-taxane (hazard ratio=0.282; 95% confidence interval=0.086-0.923; P=0.036) and BSC (hazard ratio=0.015; 95% confidence interval = 0.003-0.083; P<0.001) groups. Overall survival was also significantly longer in the taxane group than in the other groups. A taxane regimen may be more effective than a non-taxane regimen for treating patients with metastatic angiosarcoma.